Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2026)

Avalo Therapeutics has reported Non-Current Deferred Tax Liability for 10 years, with the latest figure at $446000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deferred Tax Liability rose 60.43% year-over-year to $446000.0; the trailing twelve-month figure through Mar 2026 stood at $446000.0 (up 60.43% YoY), and the FY2025 full-year result was $434000.0, down 69.65% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $446000.0, up from $434000.0 in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $1.4 million in Q4 2024, with the low at $122000.0 in Q1 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $283294.1 across 5 years, with a median of $162000.0 in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability jumped 822.58% — and 2025, when it plunged 69.65%.
• Avalo Therapeutics' Non-Current Deferred Tax Liability stood at $141000.0 in 2022, then rose by 9.93% to $155000.0 in 2023, then jumped by 822.58% to $1.4 million in 2024, then sank by 69.65% to $434000.0 in 2025, then rose by 2.76% to $446000.0 in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $446000.0 (Q1 2026), $434000.0 (Q4 2025), and $304000.0 (Q3 2025), per Business Quant data.